Product Certification&
    Enterprise Certification

  • Ms.Denise Lai
    Region Sales Manager
    Tel: 0086-592-5887167

  • Mobile:0086 13459239406
  • Tel:0086-592-5887167
  • Fax:+86-592-5854960
  • URL:http://www.china-sinoway.com
  • Province/state:fujian
  • City:Xiamen
  • Street:16/F,Huicheng Comm,Complex,No839 XiaHe Rd, Xiamen,China
  • MaxCard:
Home > Products >  5-Amino-3-(Trifluoromethyl) Picolinonitrile

5-Amino-3-(Trifluoromethyl) Picolinonitrile CAS NO.573762-62-6

  • Min.Order: 25 Kilogram
  • Payment Terms: L/C,D/A,D/P,T/T,Other
  • Product Details

Keywords

  • 5-Amino-3-(Trifluoromethyl) Picolinonitrile
  • 573762-62-6
  • Apalutamide intermediate

Quick Details

  • ProName: 5-Amino-3-(Trifluoromethyl) Picolinoni...
  • CasNo: 573762-62-6
  • Molecular Formula: C7H4 F3N3
  • Application: Apalutamide intermediate
  • DeliveryTime: within 7-10 days after confirm the ord...
  • PackAge: 25kg/drum
  • Port: Beijing/Shanghai/Hangzhou
  • ProductionCapacity: 1 Metric Ton/Month
  • Purity: 99% up by HPLC
  • Transportation: by air/by sea/by sourier
  • LimitNum: 25 Kilogram

Superiority

1) Specialized in pharmaceutical industry since from 1987

2) ISO 9001:2015 & SGS audited supplier 

3) Accept better payment terms : T.T 30-60 days.on the basic of pass SINOSURE credit investigation.

5) We have warehouse in USA with quickly shipment .

6) We can do different terms of FOB ,CIF/CIP ,DDP ...

Details

5-Amino-3-(trifluoromethyl) picolinonitrile is one of key intermediates of apalutamide (N-2).

Function of Apalutamide

As a second-generation nonsteroidal androgen receptor inhibitory drugapalutamide can prevent the fusion of androgen and receptors, and block the transfer of AR to the nucleus of cancer cells. In addition, apalutamide can also control androgen and promote the growth of cancer cells.

 

The safety and efficacy of apalutamide are based on a randomized clinical trial of 1,207 patients with non-metastatic, castration-resistant prostate cancer. Patients in the trial received apalutamide or placebo. All patients also received hormone therapy, either with a gonadotropin-releasing hormone (GnRH) analog, or with surgery to lower the amount of testosterone in the body (surgical castration). Median metastasis-free survival was 40.5 months for patients taking apalutamide, compared with 16.2 months for patients taking placebo. From the above experiments, we can see that the effect of apalutamide in the treatment of prostate cancer is very significant.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog